Wall Street Zen Downgrades Delcath Systems (NASDAQ:DCTH) to Hold

Wall Street Zen downgraded shares of Delcath Systems (NASDAQ:DCTH - Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday.

DCTH has been the subject of a number of other reports. Stephens reiterated an "overweight" rating and set a $25.00 price target on shares of Delcath Systems in a report on Monday, June 23rd. HC Wainwright restated a "buy" rating and set a $29.00 target price (up previously from $24.00) on shares of Delcath Systems in a research report on Friday, May 23rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Delcath Systems presently has an average rating of "Moderate Buy" and an average target price of $24.00.

Delcath Systems Price Performance

Delcath Systems stock traded up $0.10 during mid-day trading on Friday, hitting $12.34. 837,215 shares of the company were exchanged, compared to its average volume of 427,858. The business's 50 day simple moving average is $14.75 and its two-hundred day simple moving average is $13.83. The company has a market capitalization of $429.80 million, a P/E ratio of -24.68 and a beta of 0.87. Delcath Systems has a 12-month low of $7.17 and a 12-month high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). The company had revenue of $19.80 million for the quarter, compared to analyst estimates of $16.83 million. Delcath Systems had a negative net margin of 26.38% and a negative return on equity of 29.44%. Equities research analysts predict that Delcath Systems will post -0.79 earnings per share for the current year.

Institutional Trading of Delcath Systems

Hedge funds have recently added to or reduced their stakes in the business. Quarry LP acquired a new position in shares of Delcath Systems during the 4th quarter valued at about $34,000. Quantbot Technologies LP purchased a new stake in Delcath Systems in the fourth quarter valued at approximately $66,000. Inlight Wealth Management LLC acquired a new position in Delcath Systems during the first quarter worth approximately $85,000. Graham Capital Management L.P. acquired a new position in Delcath Systems during the fourth quarter worth approximately $123,000. Finally, NBC Securities Inc. raised its stake in Delcath Systems by 99,900.0% during the first quarter. NBC Securities Inc. now owns 10,000 shares of the company's stock worth $127,000 after purchasing an additional 9,990 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.